Таргетная терапия херувизма у ребенка 9 лет
https://doi.org/10.24287/1726-1708-2018-17-3-85-92
Аннотация
Ключевые слова
гигантоклеточная репаративная гранулема,
херувизм,
денозумаб,
дети,
алендроновая кислота,
бисфосфонаты
Об авторах
А. В. Лопатин
ФГАОУ ВО «Российский университет дружбы народов»
Россия
Россия
А. Ю. Кугушев
ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова»
Россия
Россия
Кугушев Александр Юрьевич, канд. мед. наук, врач пластический хирург, детский хирург, отделение челюстно-лицевой хирургии РДКБ
119571, Москва, Ленинский просп., 117
С. А. Ясонов
ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова»
Россия
Россия
Список литературы
1. Jaffe H.L. Giant-cell reparative granuloma, traumatic bone cyst, and fibrous (fibro-osseous) dysplasia of the jawbones. Oral Surg Oral Med Oral Pathol 6: 159; 1953.
2. Hyckel P., Berndt A., Schleier P., Clement J.H., Beensen V., Peters H., Kosmehl H. Cherubism-new hypothesis on pathogenesis and therapeutic consequences. J Cranio-Maxillofac Surg 2005; 33 (1): 61–8.
3. Lo B., Faiyaz-Ul-Haque M., Kennedy S., Aviv R., Tsui L.C., Teebi A.S. Novel mutation in the gene encoding c-Abl-binding protein SH3BP2 causes cherubism. Am J Med Genet A 2003; 121A (1): 37–40.
4. Meng X.M., Yu S.F., Yu G.Y. Clinico-pathological study of 24 cases of cherubism. Int J Oral Max Surg 2005; 34 (4): 350–6.
5. Anderson D.E., McClendon J.L. Cheru-bism-hereditary fibrous dysplasia of the jaws; I genetic considerations. Oral Surg Oral Med Oral Pathol 1962; 15 (Suppl 2): 5–16.
6. Tiziani V., Reichenberger E., Buzzo C.L., Niazi S., Fukai N., Stiller M., Peters H., et al. The gene for cherubism maps to chromosome 4h16. Am J Hum Genet 1999; 65: 158–66.
7. Ueki Y., Tiziani V., Santanna C., Fukai N., Maulik C., Garfinkle J., Ninomiya C., et al. Reichenberger E. Mutations in the gene encoding c-Abl-binding protein SH3BP2 cause cherubism. Nat Genet 2001; 28: 125–6.
8. O'Connell J.E., Bowe C., Murphy C., Toner M., Kearns G.J. Aggressive giant cell lesion of the jaws: A review of management options and report of a mandibular lesion treated with denosumab. Oral Surg Oral Med Oral Pathol Oral Radiol 2015; 120: e191.
9. Skubitz K.M., Cheng E.Y., Clohisy D.R., Thompson R.C., Skubitz A.P. Gene expression in giant-cell tumors. J Lab Clin Med 2004; 144: 193–200.
10. Rutkowski P.I., Ferrari S., Grimer R.J., Stalley P.D., Dijkstra S.P., Pienkowski A., et al. Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone. Ann Surg Oncol 2015; 22 (9): 2860–8.
11. Branstetter D.G., Nelson S.D., Manivel J.C., Blay J.Y., Chawla S., Thomas D.M., et al. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res 2012; 18: 4415–24.
12. Karras N.A. Denosumab Treatment of Metastatic Giant-Cell Tumor of Bone in a 10-Year-Old Girl. J Clin Oncol 2013 Apr 20; 31 (12): e200–e202.
13. Kobayashi E., Setsu N. Osteosclerosis induced by denosumab.Lancet 2015 Feb 7; 385 (9967): 539.
14. Bredell M., Rordorf T., Kroiss S., Rücker M., Fritz Zweifel D., Rostetter C. Denosumab as a Treatment Alternative for Central Giant Cell Granuloma: A Long-Term Retrospective Cohort Study. J Oral Maxillofac Surg 2017: 1–10.
15. Balke M., Ahrens H., Streitbuerger A., Koehler G., Winkelmann W., Gosheger G., Hardes J. Treatment options for recurrent giant cell tumors of bone. J Cancer Res Clin Oncol 2009; 135: 149–58.
16. Thomas D., Henshaw R., Skubitz K., Chawla S., Staddon A., Blay J.Y., et al. Denosumab in patients with giant-cell tumour of bone: An openlabel, phase 2 study. Lancet Oncol 2010; 11: 275–80.
17. Lipton A., Jacobs I. Denosumab: Benefits of RANK ligand inhibition in cancer patients. Curr Opin Support Palliat Care 2011; 5: 258–64.
18. Rostetter C., Rordorf T., Essig H., Zweifel D., Schumann P., Rücker M., Bredell M. New approach to treatment of giant granula with denosumab. A case example. Swiss Dent J 2017; 127: 520 (in German).
19. Tarsitano A., Del Corso G., Pizzigallo A., Marchetti C. Aggressive central giant cell granuloma of the mandible treated with conservative surgical enucleation and interferon-alpha-2a: Complete remission with long-term follow-up. J Oral Maxillofac Surg 2015; 73: 2149.
20. Naidu A., Malmquist M.P., Denham C.A., Schow S.R. Management of central giant cell granuloma with subcutaneous denosumabtherapy. J Oral Maxillofac Surg 2014; 72: 2469.
21. Schreuder W.H., Coumou A.W., Kessler P.A., de Lange J. Alternative pharmacologic therapy for aggressive central giant cell granuloma:Denosumab. J Oral Maxillofac Surg 2014; 72: 1301.
22. Gupta B., Stanton N., Coleman H., White C., Singh J. A novel approach to the management of a central giant cell granuloma with denosumab: A case report and review of current treatments. J Craniomaxillofac Surg 2015; 43: 1127.
23. Pham Dang N., Longeac M., Picard M., Devoize L., Barthélémy I. Central giant cell granuloma in children: Presentation of different therapeutic options.Rev Stomatol Chir Maxillofac Chir Orale 2016; 117: 142 (in French).
24. Skubitz K.M. Giant cell tumor of bone: current treatment options. Curr Treat Options Oncol 2014; 15: 507.
25. Ruggiero S.L., Dodson T.B., Fantasia J., Goodday R., Aghaloo T., Mehrotra B., O'Ryan F. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw – 2014 Update. J Oral Maxillofac Surg 2014; 72: 1938.
26. Saad D., Saad P. Report of a jaw osteonecrosis possibly caused by denosumab. Eur J Oral Implantol 2017;10 (2): 213–22.
27. Demirel F., Esen I., Tunc B., Tavil B. Scarcity despite wealth: Osteopetrorickets. J Pediatr Endocrinol Metab 2010; 23: 931–4.
Рецензия
Для цитирования:
Лопатин А.В., Кугушев А.Ю., Ясонов С.А. Таргетная терапия херувизма у ребенка 9 лет. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2018;17(3):85-92. https://doi.org/10.24287/1726-1708-2018-17-3-85-92
For citation:
Lopatin A.V., Kugushev A.Yu., Yasonov S.A. Target therapy of cherubism in a 9 years old child. Pediatric Hematology/Oncology and Immunopathology. 2018;17(3):85-92. (In Russ.) https://doi.org/10.24287/1726-1708-2018-17-3-85-92
Просмотров: 1115
Послать статью по эл. почте 
